Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04488081 · ClinicalTrials.gov registry record · Phase 2
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
A Phase 2 study of COVID-19, sponsored by QuantumLeap Healthcare Collaborative.
- Active
- Registry status
- Phase 2
- Development phase
- 1,500
- Enrollment target
- 20
- Study locations
NCT04488081 is a Phase 2 study of COVID-19 that is active but no longer recruiting, run by QuantumLeap Healthcare Collaborative. The registered enrollment target is 1,500 participants, below the 55,207-participant average among 203 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04488081, a Phase 2 study of COVID-19, is active but no longer recruiting, sponsored by QuantumLeap Healthcare Collaborative.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Remdesivir
- DRUG Icatibant
- DRUG Imatinib Mesylate
- DRUG Cenicriviroc
Study Locations (20)
California
- UC Davis Medical Center - Davis
- UC Irvine Medical Center - Irvine
- Long Beach Memorial Medical Center - Long Beach
- Kaiser LAMC - Los Angeles
- University of Southern California - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- University of California San Francisco (UCSF) - San Francisco
Connecticut
- Yale Cancer Center - New Haven
- Stamford Health - Stamford
Florida
- University of Miami - Coral Gables
- University of Florida - Gainesville
Michigan
- University of Michigan - Ann Arbor
- Corewell Health - Grand Rapids
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado - Aurora
District of Columbia
- Georgetown University - Washington D.C.
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2020-07-31 |
| Est. Completion | 2030-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04488081
The ClinicalTrials.gov registry entry for NCT04488081 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,207-participant average among 203 other COVID-19 trials with a reported enrollment target (97% lower). The listed sponsor is QuantumLeap Healthcare Collaborative, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT04488081 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT04488081 about?
NCT04488081 is a clinical study titled "I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients". The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as...
What is the current status of trial NCT04488081?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,500 participants. The study started on 2020-07-31. Estimated completion is 2030-07-31.
What conditions does trial NCT04488081 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04488081?
The interventions under investigation include: Dexamethasone (DRUG), Remdesivir (DRUG), Icatibant (DRUG), Imatinib Mesylate (DRUG), Cenicriviroc (DRUG).
Who is sponsoring clinical trial NCT04488081?
This trial is sponsored by QuantumLeap Healthcare Collaborative, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04488081 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.